Possibly. But only under medical supervision
Catch up on global daily news
Compelling long reads
Tune into captivating conversations
Watch engaging short films
Behind the scenes at The Economist
GLP-1 receptor agonists like semaglutide are being used off-label by healthy people hoping to slow ageing, despite limited…
A handpicked article read aloud from the latest issue of The Economist
GLP-1s offer a rare insight into the social and economic effects of carrying extra weight
Pharma’s newest obsession involves mimicking the system that keeps people awake
The expiry of patents in China, India and elsewhere will boost uptake dramatically
New versions of drugs like Wegovy, Ozempic, Mounjaro and Zepbound, including pills, will be easier to take, more effective and…
